In recognition of AML World Awareness Day, Servier Canada is highlighting the progress made in precision medicine for Acute Myeloid Leukemia (AML).
Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial. “New novel therapies ...
A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results